Clinical trials: Post-COVID Condition
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Paxlovid for Treatment of Long Covid
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid.
- Trial name
- STOP-PASC (NCT05576662)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Stanford University
COVID-19 Infection
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study.
- Trial name
- E-APLICOV-PC (NCT05121740)
- Testing
- Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day
- Where
- 10 sites in Spain
- Volunteers
- 34 people
- Sponsor
- PharmaMar
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Sequelae of; Infection
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers").
- Conditions
- Covid19, Sequelae of; Infection, Cognitive Symptom
- Trial name
- NCT04809974
- Testing
- Niagen
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Long COVID
Fluvoxamine for Long COVID-19
This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in…
- Trial name
- NCT05874037
- Testing
- Fluvoxamine
- Where
- United States
- Volunteers
- 191 people
- Sponsor
- Washington University School of Medicine
Long COVID, Pain
Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID
The goal of this preliminary study is to test methods and procedures to be used in a fully-powered trial to evaluate acupuncture treatment effectiveness.
- Trial name
- NCT06476496
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- University of Washington
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
Post COVID Syndrome, Fatigue
Vagal Nerve Stimulation for Post COVID Fatigue
The purpose of this study is to evaluate the impact of vagal nerve stimulation on patients with post COVID syndrome who have fatigue and headache.
- Conditions
- Post COVID Syndrome, Fatigue, Headache
- Trial name
- NCT05445427
- Testing
- vagal nerve stimulator
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
SARS-CoV-2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute…
- Trial name
- PROTECT-APT 1 (NCT05954286)
- Testing
- Upamostat
- Where
- 6 sites in United States, South Africa and 2 more
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Covid19, SARS-CoV2 Infection
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
- Trial name
- NCT04952402
- Testing
- Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Long COVID, Chronic Fatigue Syndrome
Vagus Nerve Stimulation as Treatment for Long Covid
Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using…
- Trial name
- NCT05608629
- Testing
- Transcutaneous Non-Invasive Vagus Nerve Stimulation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Long COVID, Post Acute Sequelae of COVID-19
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID.
- Conditions
- Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
- Trial name
- PREVAIL-LC (NCT06161688)
- Testing
- Ensitrelvir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Timothy Henrich
COVID-19, Corona Virus Infection
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons…
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Trial name
- NCT04328961
- Testing
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Where
- 8 sites in United States
- Volunteers
- 943 people, healthy volunteers welcome
- Sponsor
- University of Washington
Long COVID, Long COVID-19
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Trial name
- NCT05965752
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- 24 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Tachycardia, Dyspnea
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC).
- Conditions
- Tachycardia, Dyspnea, COVID-19
- Trial name
- PEACE (NCT05096884)
- Testing
- Metoprolol Succinate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hackensack Meridian Health
Covid19
Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-acute sequelae SARS-CoV-2 infection (PASC) and patients that have recovered from COVID without lingering symptoms.
- Trial name
- NCT04860869
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Cognitive Impairment, Long COVID
Addressing Cognitive Fog in Long-COVID-19 Patients
This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID.
- Trial name
- NCT05597722
- Testing
- Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eva Szigethy
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.